Grabowski, M. KatePatel, Eshan U.Nakigozi, GertrudeSsempijja, VictorSsekubugu, RobertSsekasanvu, JosephNdyanabo, AnthonyKigozi, GodfreyNalugoda, FredGray, Ronald H.Kalibbala, SarahSerwadda, David M.Laeyendecker, OliverWawer, Maria J.Chang, Larry W.Quinn, Thomas C.Kagaayi, JosephTobian, Aaron A. R.Reynolds, Steven J.2022-01-202022-01-202021Grabowski, M. K., Patel, E. U., Nakigozi, G., Ssempijja, V., Ssekubugu, R., Ssekasanvu, J., ... & Reynolds, S. J. (2021). Prevalence and Predictors of Persistent Human Immunodeficiency Virus Viremia and Viral Rebound After Universal Test and Treat: A Population-Based Study. The Journal of infectious diseases, 223(7), 1150-1160. DOI: 10.1093/infdis/jiab02110.1093/infdis/jiab021https://nru.uncst.go.ug/xmlui/handle/123456789/1367UNAIDS targets for human immunodeficiency virus (HIV) epidemic control by 2030 include that 86% of all HIV-positive persons be on antiretroviral therapy (ART) and achieve HIV viral load (VL) suppression [1]. The major policy initiative underpinning this target is universal test and treat (UTT), whereby all HIV-positive persons, irrespective of CD4 count or severity of illness, are immediately prescribed ART [2]. In sub-Saharan Africa, which accounts for more than half of all new HIV diagnoses globally, there has been considerable progress in increasing ART coverage [enAfricaCohort studiesHIV preventionUniversal test and treatViral suppressionArticle